NCT04849650已完成1 期
An Open Label Study of the Pharmacokinetics of Intravenous and Oral Amisulpride in Adults With Severe Renal Impairment and Healthy Control Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- PK: Amisulpride plasma exposure (AUC) after a single IV dose
研究概览
简要总结
The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease. In addition it is important to understand how well tolerated Amisulpride is in this patient population. Healthy adults will be studied to provide a comparison.
详细描述
This will be an open-label, non-randomised, pharmacokinetic study in
- 6 adult subjects with severe renal impairment and end-stage renal disease (i.e., eGFR < 30 mL/min/1.73 m2) without dialysis.
- 6 matched healthy subjects (control group).
Each subject will be given a single dose of 10 mg IV Amisulpride, followed by a single dose of 10 mg oral Amisulpride given 24 hours later.
Subjects will be admitted to the clinic on Day -1. Dosing will start the following day (Day 1). Serial blood samples will be taken during Days 1-3 to assess the pharmacokinetics of Amisulpride. Subjects will remain in clinic over the duration of the study and will be discharged when the final blood sample is drawn on Day 3.
The tolerability /safety of Amisulpride will be assessed by clinical chemistry and haematology assessments, vital signs, electrocardiograms (ECG), physical examination and adverse event reporting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
盲法说明
All parties will have knowledge of the interventions assigned to each subject.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Subjects
- •Age 18 to 75 years of age at time of signing ICF.
- •Body mass index (BMI) between 18 and 38 kg/m
- •Must be willing and able to communicate and participate in the whole study.
- •Must provide written informed consent.
- •Must agree to use an adequate method of contraception
- •Healthy as defined by:
- •The absence of clinically significant illness and surgery within 4 weeks prior to dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Principal Investigator;
- •The absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic (including cholecystectomy), and metabolic disease;
- •The absence of clinically significant history of lactic acidosis and severe hepatomegaly with steatosis;
- •The absence of history of suicidal tendency, disposition to seizures, state of confusion, or clinically relevant psychiatric diseases.
- •Normal renal function, i.e., eGFR or creatinine clearance ≥ 90 mL/min/1.73 m2 as calculated using the MDRD4 or Cockcroft-Gault equation; at the Principal Investigator's discretion, 24 hour creatinine clearance may be conducted to determine renal function.
- •Matched to subjects with severe renal impairment for gender, age (± 10 years), and BMI (± 15%) to the extent possible.
- •Inclusion Criteria: Renal Impaired Subjects
- •Age 18 to 75 years of age at time of signing ICF.
- •Body mass index (BMI) between 18 and 38 kg/m
- •Must be willing and able to communicate and participate in the whole study.
- •Must provide written informed consent.
- •Must agree to use an adequate method of contraception
- •A diagnosis of renal impairment that has been stable, without significant change in overall disease status in the 3 months prior to screening as determined by the Principal Investigator, with no requirement for dialysis, and an eGFR at screening < 30 mL/min/1.73 m2 calculated using the MDRD4 equation.
排除标准
- •Healthy Subjects
- •Subjects who have received any IMP in a clinical research study within the 30 days prior to IMP administration on this study.
- •Subjects who are study site, CRO or sponsor employees, or immediate family members of a study site, CRO or sponsor employee.
- •Subjects who have previously been enrolled in this study.
- •Women who are pregnant or breastfeeding.
- •Subjects who have received amisulpride for any indication within the 30 days prior to dosing.
- •Allergy to amisulpride or any of the excipients of amisulpride.
- •History of any drug or alcohol abuse in the 2 years prior to screening.
- •Regular alcohol consumption >21 units per week in the 6 months prior to screening.
- •Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
- •History of epilepsy in the 5years prior toscreening.
- •History of clinically significant syncope.
- •Family history of sudden death.
- •Family history of premature cardiovascular death.
- •Clinically significant history or family history of congenital long QT syndrome (e.g.
- •Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.
- •History of clinically significant arrhythmias or ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
- •Conditions predisposing the volunteer to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
- •Clinically significant abnormal biochemistry,haematology or urinalysis at screening as judged by the investigator
- •Positive drugs of abuse test result
- •Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results at screening.
- •Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
- •Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2,000 mg per day acetaminophen) or herbal remedies in the 14 days before IMP administration
- •Administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
- •Failure to satisfy the investigator of fitness to participate for any other reason.
- •Exclusion Criteria: Renal Impaired Subjects
- •Subjects who have received any IMP in a clinical research study within the 30 days prior to IMP administration on this study.
- •Subjects who are study site, CRO or sponsor employees, or immediate family members of a study site, CRO or sponsor employee.
- •Subjects who have previously been enrolled in this study.
- •Women who are pregnant or breastfeeding.
- •Subjects who have received amisulpride for any indication within the 30 days prior to dosing.
- •Allergy to amisulpride or any of the excipients of amisulpride.
- •History of any drug or alcohol abuse in the 2 years prior to screening.
- •Regular alcohol consumption >21 units per week in the 6 months prior to screening.
- •Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
- •History of epilepsy in the 5years prior to screening.
- •History of clinically significant syncope.
- •Family history of sudden death.
- •Family history of premature cardiovascular death.
- •Clinically significant history or family history of congenital long QT syndrome (e.g.
- •Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.
- •History of clinically significant arrhythmias or unstable ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
- •Positive drugs of abuse test result, unless caused by a documented prescription drug.
- •Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results at screening.
- •Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
- •Administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
- •Failure to satisfy the investigator of fitness to participate for any other reason.
研究组 & 干预措施
Renal Impairment Subjects
Experimental
10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
干预措施: Amisulpride IV (Drug)
Renal Impairment Subjects
Experimental
10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
干预措施: Amisulpride Oral Tablet (Drug)
Healthy Subjects
Experimental
10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
干预措施: Amisulpride IV (Drug)
Healthy Subjects
Experimental
10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
干预措施: Amisulpride Oral Tablet (Drug)
结局指标
主要结局
PK: Amisulpride plasma exposure (AUC) after a single IV dose
时间窗: 24 hours
Amisulpride plasma exposure after a single IV dose measured as the area under the concentration-time curve (AUC) between study drug administration and the time at which the following-day oral dose of Amisulpride is given
次要结局
- PK: Amisulpride plasma exposure (AUC) after a single oral dose(24 hours)
- PK: T1/2(24 hours)
- PK: Clearance(24 hours)
- PK: Vd(24 hours)
- Safety: AE(From first study drug administration until discharge (4 days))
- PK: Cmax(24 hours)
- PK: Tmax(24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.Ulcerative ColitisNCT00254618Warner Chilcott34
已完成
1 期
A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male VolunteersHealthyNCT01791231Johnson & Johnson Pharmaceutical Research & Development, L.L.C.6
已完成
1 期
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and TolerabilityPharmacokineticsPharmacodynamicsHealthy SubjectsEffect of RaceNCT01958047Astellas Pharma Europe B.V.64
已完成
1 期
Mass Balance Study of ASP1941Healthy SubjectsNCT01302132Astellas Pharma Inc6
已完成
1 期
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisEnd-Stage Renal DiseaseNCT02289703Janssen Research & Development, LLC16